Biogen Reports observational Data for Bictegravir in Alopecia areata

Biogen today announced observational results for bictegravir in patients with alopecia areata. The study demonstrated that bictegravir improves functional outcomes compared to standard of care or placebo. These results provide important insights into the treatment of alopecia areata and support the continued development of bictegravir in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.